Experimental CARS Therapy Breaks Through Relapsed CLL

ATLANTA (IMNG) - Responses to chimeric antigen receptor-modified T-cell therapy have been sustained beyond 2 years in a small cohort of patients with advanced chronic lymphocytic leukemia and no other...
Source: OncologySTAT Latest News - Category: Cancer & Oncology Source Type: news